<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00134186</url>
  </required_header>
  <id_info>
    <org_study_id>PCYC-0219</org_study_id>
    <nct_id>NCT00134186</nct_id>
  </id_info>
  <brief_title>Study of Motexafin Gadolinium for the Treatment of Renal Cell (Kidney) Cancer</brief_title>
  <official_title>Phase II Trial of Motexafin Gadolinium for Treatment of Metastatic Renal Cell Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pharmacyclics LLC.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pharmacyclics LLC.</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to find out if renal cell (kidney) cancer that has spread to
      other parts of the body will respond to treatment with motexafin gadolinium (MGd).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical response rate (CP, PR) to MGd in patients with confirmed progressive RCC (renal cell carcinoma)</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical benefit rate (complete response [CR], partial response [PR], stable disease [SD])</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival and survival at 6 and 12 months</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of clinical response</measure>
  </secondary_outcome>
  <enrollment>43</enrollment>
  <condition>Carcinoma, Renal Cell</condition>
  <condition>Urogenital Neoplasms</condition>
  <condition>Urologic Neoplasms</condition>
  <condition>Kidney Neoplasms</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>motexafin gadolinium</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ≥ 18 years old

          -  Histologically confirmed renal cell carcinoma with clinically or pathologically
             confirmed progression

          -  Ineligible for interleukin-2 (IL-2) treatment and/or have had 2 or fewer prior
             treatments

          -  Measurable disease

          -  Hemoglobin ≥ 9 mg/dL

          -  ECOG performance status of 0, 1, or 2

          -  Willing and able to provide written informed consent

        Exclusion Criteria:

          -  Inadequate bone marrow, renal and liver function by laboratory criteria

               -  Absolute neutrophil count &lt; 1500/µL;

               -  Platelet count &lt; 100,000/µL;

               -  AST or ALT &gt; 2 x upper limit of normal (ULN);

               -  Alkaline phosphatase &gt; 5 x ULN;

               -  Total bilirubin &gt; 2 x ULN;

               -  Creatinine &gt; 2.0 mg/dL.

          -  Evidence of central nervous system metastases within past year

          -  Uncontrolled hypertension

          -  Known history of porphyria, G6PD deficiency or HIV
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert J Amato, D.O.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Methodist Hospital Genitourinary Oncology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Methodist Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 22, 2005</study_first_submitted>
  <study_first_submitted_qc>August 22, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 24, 2005</study_first_posted>
  <last_update_submitted>March 2, 2007</last_update_submitted>
  <last_update_submitted_qc>March 2, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 5, 2007</last_update_posted>
  <keyword>Kidney cancer</keyword>
  <keyword>Renal cell carcinoma</keyword>
  <keyword>Motexafin gadolinium</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
    <mesh_term>Kidney Neoplasms</mesh_term>
    <mesh_term>Urogenital Neoplasms</mesh_term>
    <mesh_term>Urologic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Motexafin gadolinium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

